TuHURA Biosciences (HURA) Depreciation & Amortization (CF) (2021 - 2026)
TuHURA Biosciences (HURA) posted quarterly Depreciation & Amortization (CF) of $23472.0 for Q1 2026, up 66.97% year-over-year from $14058.0 in Q1 2025, and up 4.12% quarter-over-quarter from $22544.0 in Q4 2025.
TuHURA Biosciences (HURA) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
TuHURA Biosciences' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $23472.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 66.97% year-over-year to $23472.0; the TTM figure through Mar 2026 stood at $80679.0 (down 55.93% YoY), while the FY2025 annual figure was $71265.0, down 38.94% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $23472.0, up from $22544.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $99075.0 in Q3 2024, with the low at $13371.0 in Q2 2025.
- The 5-year median for Depreciation & Amortization (CF) is $15000.0 (2022), against an average of $27870.2.
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) surged 560.5% in 2024, then sank 80.88% in 2025.
- TuHURA Biosciences' Depreciation & Amortization (CF) stood at $15000.0 in 2022, then surged by 100.0% to $30000.0 in 2023, then jumped by 230.25% to $99075.0 in 2024, then plunged by 77.25% to $22544.0 in 2025, then advanced by 4.12% to $23472.0 in 2026.
- Business Quant data shows HURA's Depreciation & Amortization (CF) at $23472.0 in Q1 2026, $22544.0 in Q4 2025, and $21292.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | 28,104.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,472.00 |
| Mar 31, 2026 | 23,472.00 |
| Dec 31, 2025 | 22,544.00 |
| Dec 31, 2025 | 22,544.00 |
| Sep 30, 2025 | 21,292.00 |
| Sep 30, 2025 | 21,292.00 |
| Jun 30, 2025 | 13,371.00 |
| Jun 30, 2025 | 13,371.00 |
| Mar 31, 2025 | 14,058.00 |
| Mar 31, 2025 | 14,058.00 |
| Sep 30, 2024 | 99,075.00 |
| Sep 30, 2024 | 99,075.00 |
| Jun 30, 2024 | 69,934.00 |
| Jun 30, 2024 | 69,934.00 |
| Mar 31, 2024 | 34,307.00 |
| Mar 31, 2024 | 34,307.00 |
| Dec 31, 2023 | 30,000.00 |
| Dec 31, 2023 | 30,000.00 |
| Sep 30, 2023 | 15,000.00 |
| Sep 30, 2023 | 15,000.00 |